References
- Ajmera S., Danenberg P. V. J. med. Chem. 1982; 25: 999–1002
- Alarcon R. A., Meienhofer J. Nature New Biol. 1971; 233: 250–252
- Aoshima M., Tsukagoshi S., Sakurai Y., Ohishi J., Ishida T., Kobayashi H. Cancer Res. 1977; 37: 2481–2486
- Arnold H., Bourseaux F., Brock N. Naturwissenschaften 1958; 45: 64–66
- Au J. L., Rustum Y. M., Minowada J., Srivasta B. J. Biochem. Pharmacol. 1983; 32: 541–546
- Bardos T. J., Chmielewicz Z. F., Hebborn P. Ann. N.Y. Acad. Sci. 1969; 163: 1006–1025
- Beisler K. A. J. Med. Chem. 1978; 204–208
- Brock N. Structure-activity Relationships of Anti-tumour Agents, D. N. Reinboudt, T. A. Connors, H. M. Pinedo, K. W. van den Poll. Martinus Nijhoff, The Hague 1983; 239–267
- Bukhari A., Connors T. A., Gilsenan A. M., Ross W. C. J., Tisdale M. J., Warwick G. P., Wilman D. E. V. J. natn. Cancer Inst. 1973; 50: 243–247
- Chatterji D. C., Galleli J. F. J. Pharm. Sci. 1979; 68: 822–826
- Chakravarty P. K., Carl P. L., Weber M. J., Katznellenbogen J. A. J. Med. Chem. 1983; 26: 663–638
- Colvin M., Padgett C. A., Fenselau C. Cancer Res. 1973; 33: 915–918
- Connors T. A. Structure-activity Relationships of Anti-tumour Agents, D. N. Reinhoudt, T. A. Connors, H. M. Pinedo, K. W. van den Poll. Martinus Nijhoff, The Hague 1983; 47–57
- Connors T. A., Whisson M. Nature 1966; 210: 866–867
- Connors T. A., Cox P. J., Farmer P. B., Foster A. B., Jarman M. Biochem. Pharmac. 1974; 23: 115–129
- Connors T. A., Farmer P. B., Foster A. B., Gilsenan A. M., Jarman M., Tisdale M. J. Biochem. Pharmac. 1973; 22: 1971–1980
- Dalton C., Hebborn P. Biochem. Pharmac. 1965; 14: 1567–1576
- Druckrey H., Brock N. Muenchen Med. Wschr. 1961; 103: 777–779
- Frako A. J., Chapman J. D. Br. J. Cancer 1982; 45: 694–699
- Goldacre R. J., Whisson M. E. Br. J. Cancer 1966; 20: 801–812
- Hilgard P., Brock N. Investigational New Drugs 1984; 2: 131–132
- Hill D. L., Kirk M. C., Struck V. F. J. Am. Chem. Soc. 1970; 92: 3207–3208
- Hill D. L., Laster W. R., Struck R. F. Cancer Res. 1972; 32: 658–665
- Ho D. H. W., Neil G. L. Cancer Res 1977; 37: 1640–1643
- Hoshi A., Kanzawa F., Kuretani K. Gann 1972; 63: 353–360
- Kennedy K. A., Teicher B. A., Rockwell S., Sartorelli A. C. Biochem. Pharmac. 1980; 29: 1–8
- Manson M. M., Legg R. F., Watson J. V., Green J. A., Neal G. E. Carcinogenesis 1981; 2: 661–670
- Meyer R. B., Stone T. E., Ullman B. J. med. Chem. 1979; 22: 811–815
- Mizoguchi H., Orlowski M., Wilk S., Green J. P. Eur. J. Pharmac. 1979; 57: 239–245
- Orlowski M., Mizoguchi H., Wilk S. J. Pharmac. exp. Ther. 1980; 212: 167–172
- Peters T. J., Seymour C. A., Wells G., Fakunle F., Neale G. Br. med. J. 1977; 1: 1576
- Repta A. J., Rawson B. J., Shaffer R. D., Sloan K. B., Bodor N., Higuchi T. J. Pharm. Sci. 1975; 64: 392–396
- Sloan K. B., Hashida M., Alexander J., Bodor N., Higuchi T. J. Pharm. Sci. 1983; 72: 372–378
- Tsou K. C., Su H. C. F. J. med. Chem. 1963; 6: 693–696
- Whisson M. E., Connors T. A. Nature 1965; 206: 689–691
- Workman P. Cancer Topics 1982; 4: 22–23